

# Gastrointestinal (GI) Disease-Oriented Team

---

Clinical Research Treatment Trial Flowchart



### NEOADJUVANT

**CCTG-CO32**  
(NEO-RT trial)

**(opened 4/29/24)**  
Coord: P. Yang

PI: Dr. Zell  
Accrual: 3/5

### ADJUVANT

**NRG-GI008/CIRCULATE**  
(ctDNA guided tx)

**(opened 9/14/22)**  
Coord: A. Ballard

PI: Dr. Zell  
Accrual: 5/10

### INTRA-OPERATIVE

**UCI 24-103**  
(Y90 Resin Spheres vs  
SOC of mCRC liver metastases)

Coord: TBD  
PI: Dr. Abi-Jaoudeh  
Pending activation

### MOLECULAR FAILURE

**UCI 20-43**  
(TAS102 + irinotecan)

**(opened 5/24/22)**  
Coord: M. Bauk

PI: Dr. Dayyani  
Accrual: 14/17



### 1L METASTATIC

#### A022101

(at least 4 months of chemo once metastatic disease is confirmed)

Coord: A. Ballard

PI: Dr. Eng  
Accrual: 1/2

#### UCI 25-155

(Ivonescimab + FOLFOX vs Bevacizumab + FOLFOX)

**(opened 2/26/26)**

Coord: M. Bauk  
PI: Dr. Dayyani  
Accrual 0/15

#### UCI 25-196

(Pumitamidg + Chemo vs Bevacizumab + Chemo)

**(opened 4/6/26)**

Coord: N. Ferrand  
PI: Dr. Dayyani  
Accrual 0/5

### 2L METASTATIC

#### ETCTN 10670

(Abemaciclib + 5-Fluorouracil)

**(opened 4/8/25)**

Coord: M. Nguyen

PI: Dr. Dayyani  
Accrual: 4/8

#### UCI 23-85

(BA3182 + (EPCAM)/CD3 Antibody)

**(opened 9/19/24)**

Coord: P. Yang

PI: Dr. Valerin  
Accrual: 7/18

#### ETCTN 10605

(ZEN-3694 + Cetuximab and Encorafenib; BRAF V600E)

**(opened 1/14/26)**

Coord: M. Nguyen

PI: Dr. Dayyani  
Accrual: 0/3

### 3L METASTATIC

#### UCI 24-142

(VET3-TGI +/- pembrolizumab)

**(opened 3/7/25)**

Coord: N. Ferrand

PI: Dr. Uchio  
Accrual: 1/4

#### UCI 24-93

(Fruquintinib)

**(opened 5/28/25)**

Coord: M. Bauk

PI: Dr. Dayyani  
Accrual: 5/14

**UCI 25-149**

(Metformin use for Pseudomyxoma  
Peritonei secondary to appendiceal  
mucinous neoplasms)

Coord: TBD

PI: Dr. Eng  
Pending activation

Newly Diagnosed

Advanced/Metastatic

■ Open to Accrual   ■ Low Accruing   ■ Pending Activation/Suspended

## Neoadjuvant

UCI 21-191  
 (SOC w/ ctDNA testing)  
 (opened 6/27/25)  
 Coord: A. Ballard

PI: Dr. Dayyani  
 Accrual: 12/20

UCI 23-184  
 (Pafolacianine for Imaging of  
 Peritoneal Carcinomatosis)

Coord: L. Mejia  
 PI: Dr. Senthil  
 Accrual: 8/10

## ESCC

UCI 24-77  
 (I-DXd)

(opened 2/5/26)  
 Coord: C. Jonsson

PI: Dr. Dayyani  
 Accrual: 0/5

## Newly Diagnosed Metastatic

A022102  
 (mFOLFIRINOX +/-  
 Nivolumab vs. FOLFOX +/-  
 Nivolumab)

Coord: M. Bauk  
 PI: Dr. Dayyani  
 Accrual: 9/14

EA2234  
 (IP/IV Paclitaxel + IV 5-FU +  
 LV VS SOC)

(opened 8/28/25)  
 Coord: L. Mejia  
 PI: Dr. Senthil  
 Accrual: 10/65

UCI 21-10  
 (FOLFOX + nivo + TJ033721  
 (anti-CLDN18.2 + anti-4-1BB)

Coord: M. Nguyen; C.  
 Jonsson  
 PI: Dr. Dayyani  
 Accrual: 33/50

## Recurrent

UCI 16-94  
 (Tirapazamine, Nivolumab)

(opened 6/15/23)  
 Coord: M Duron

PI: Dr. Abi-Jaoudeh  
 Accrual: 35/48

UCI 24-49  
 (Beamion BCGC-1:  
 Oral Zongertinib + Trastuzumab  
 Deruxtecan or + Trastuzumab  
 Emtansine)

(opened 10/22/24)

Coord: M. Nguyen  
 PI: Dr. Dayyani  
 Accrual: 3/10

UCI 23-173  
 (ICI in ARID1a Mu)  
 Coord: TBD  
 PI: Dr. Dayyani  
Pending activation

## HER-2

**ETCTN-10495**  
(DS8201a + Neratinib)  
**(opened 3/5/25)**  
Coord: M. Nguyen

PI: Dr. Dayyani  
Accrual: 2/7

**UCI 24-49**  
(Beamion BCGC-1:  
Oral Zongertinib +  
Trastuzumab Deruxtecan)  
**(opened 10/22/24)**

Coord: M. Nguyen  
PI: Dr. Dayyani  
Accrual: 3/10

## KRAS

**UCI 25-163**  
(BBO-11818)

Coord: K. Buttigieg

PI: Dr. Arter  
Pending activation

Open to Accrual

## EGFR

Low Accruing

## CLDN18.2

**UCI 21-10**  
(FOLFOX + nivo +  
TJ033721 (anti-CLDN  
18.2 + anti-4-1BB)

Coord: M. Nguyen

PI: Dr. Dayyani  
Accrual: 33/50

Pending Activation/Suspended



# Advanced Solid Tumor

■ Open to Accrual

■ Low Accruing

■ Pending Activation/Suspended

**UCI 23-85**  
(BA3182 + (EPCAM)/CD3 Antibody)

**(opened 9/19/24)**

Coord: P. Yang  
PI: Dr. Valerin  
Accrual: 7/18

**UCI 22-26**  
(Androgen and glucocorticoid receptor antagonist)

Coord: B. Nguyen  
PI: Dr. Dayyani  
Accrual: 11/16

**ETCTN-10579**  
(ZEN003694 (ZEN-3694) + capecitabine)

**(opened 10/27/23)**

Coord: P. Yang  
PI: Dr. FC Lee  
Accrual: 2/4

**UCI 21-241**  
(ALK inhibitor NLV-655)

**(opened 10/4/22)**

Coord: A. Ballard  
PI: Dr. Nagasaka  
Accrual: 20/25

**UCI 25-16**  
(ODM-212)

**(opened 8/29/2025)**

Coord: P. Yang  
PI: Dr. Dayyani  
Accrual: 6/10

**UCI 24-138**  
(Tarlatab in DLL3 Expressing Tumors + Neuroendocrine Neoplasms)

**(opened 10/31/2025)**

Coord: N. Ferrand  
PI: Dr. Park  
Accrual: 2/5

**ETCTN-10572**  
(Temozolomide + M1774)

**(opened 12/11/2025)**

Coord: M. Nguyen  
PI: Dr. Dayyani  
Accrual: 1/10

**UCI 24-113**  
(BMS-986482 +/- immunotherapy)

**(opened 9/29/2025)**

Coord: L. Mejia  
PI: Dr. Chow  
Accrual: 5/10

**UCI 24-142**  
(IV/iTu VET3-TGI +/- atezolizumab)

**(opened 3/7/2025)**

Coord: N. Ferrand  
PI: Dr. Uchio  
Accrual: 1/4

**UCI 25-75**  
(CRN09682- on SST2 expressing tumors)

**(opened 2/18/2026)**

Coord: S. Duong  
PI: Dr. Dayyani  
Accrual: 0/15

**UCI 25-190 (STOPGAP-B)**  
(IP Paclitaxel + SOC in GI Malignancies with Peritoneal Carcinomatosis)

Coord: TBD

PI: Dr. Senthil  
Pending activation



■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

**UCI 03-03**  
(Immunologic response analysis)

Coord: B. Sanchez  
PI: Dr. Imagawa  
Accrual: 336/400

(ID GenomeSig for HomoRecomboDeficiency inPC &Mismatch RepairDeficiency in Microsatellite Instable CC)  
**(opened 3/13/2025)**  
PI: Dr. Pannunzio/Dr. Valerin  
Accrual: 16/50

**UCI 24-05**  
(Riluzole for Cancer-related Cognitive Impairment)

Coord: M. Bauk  
PI: Dr. Chan  
Accrual: 26/59

**UCI 25-48**  
(Riluzole For Preventing Cognitive Dysfunction in Pts Receiving Chemo (REFOCUS))

Coord: M. Bauk  
PI: Dr. Chan  
Accrual: 4/20

# Supportive Trials